A review on golimumab in the treatment of psoriatic arthritis.

about

Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis.

P2860

Q48132042-1A131DA7-1D8E-4F2E-A5DA-FAC4133B259E

P2860

A review on golimumab in the treatment of psoriatic arthritis.

Item

http://www.wikidata.org/entity/Q53098976

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

A review on golimumab in the treatment of psoriatic arthritis.

@en

A review on golimumab in the treatment of psoriatic arthritis.

@nl

type

Item

label

A review on golimumab in the treatment of psoriatic arthritis.

@en

A review on golimumab in the treatment of psoriatic arthritis.

@nl

prefLabel

A review on golimumab in the treatment of psoriatic arthritis.

@en

A review on golimumab in the treatment of psoriatic arthritis.

@nl

P1476

A review on golimumab in the treatment of psoriatic arthritis.

@en

P2093

Hannah Jethwa

http://www.w3.org/2001/XMLSchema#string

Maria Urdaneta

http://www.w3.org/2001/XMLSchema#string

Reshma Sultan

http://www.w3.org/2001/XMLSchema#string

Sonya Abraham

http://www.w3.org/2001/XMLSchema#string

P2860

Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.

Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.

Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.

Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy--a single centre, open-label study.

Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.

Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects.

Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.

Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis.

P304

871-889

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT-2017-0063

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28838285

http://www.w3.org/2001/XMLSchema#string

A review on golimumab in the treatment of psoriatic arthritis.

about

P2860

P2860

A review on golimumab in the treatment of psoriatic arthritis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698